GLD vs IBB

SPDR Gold Shares vs iShares Biotechnology ETF

Quick take
  • GLD has the lower expense ratio at 0.40% vs 0.44% for IBB.
  • IBB pays a higher dividend yield (0.22%).

Side-by-side metrics

MetricGLDIBB
Expense ratio
Annual fee. Lower is better.
0.40%0.44%
Dividend yield
Trailing 12-month yield.
0.00%0.22%
AUM
Assets under management — bigger funds are typically more liquid.
$130.05B$9.09B
YTD return
-5.52%16.44%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.410.69
P/E ratio
24.89
Last price
$378.18$197.34
Inception
Issuer
State StreetiShares

GLD top holdings

Holdings data unavailable for GLD.

IBB top holdings

Top holdings · IBB
VRTXVertex Pharmaceuticals Inc8.07%
AMGNAmgen Inc7.82%
GILDGilead Sciences Inc6.83%
REGNRegeneron Pharmaceuticals Inc4.90%
ARGXargenx SE ADR3.75%
ALNYAlnylam Pharmaceuticals Inc3.12%
NTRANatera Inc2.89%
RVMDRevolution Medicines Inc Ordinary Shares2.78%
BIIBBiogen Inc2.46%
ILMNIllumina Inc2.07%
Sector breakdown · IBB
Healthcare100.0%

About GLD

GLD (SPDR Gold Shares) is Physically backed gold ETF. Managed by State Street, the fund carries $130.1B in assets under management, an expense ratio of 0.40%.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.